Prognostic value of bcl-2 expression in invasive breast cancer
| Autor: | P. Hellemans, A. van Oosterom, Joost Weyler, E. Van Marck, P A van Dam, Ph. Buytaert |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Adult
Oncology Cancer Research Prognostic variable medicine.medical_specialty Pathology Mammary gland Gene Expression Breast Neoplasms Biology Proto-Oncogene Mas Breast cancer Predictive Value of Tests Proto-Oncogene Proteins Internal medicine medicine Adjuvant therapy Humans Neoplasm Invasiveness Tissue Distribution Aged Aged 80 and over Carcinoma Ductal Breast Middle Aged Ductal carcinoma Progesterone Receptor Status Prognosis medicine.disease Immunohistochemistry medicine.anatomical_structure Proto-Oncogene Proteins c-bcl-2 Evaluation Studies as Topic Lymphatic Metastasis Predictive value of tests Female Lymph Nodes Research Article |
| Zdroj: | The British journal of cancer British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| Popis: | Expression of the bcl-2 proto-oncogene was studied immunohistochemically in 251 invasive ductal breast carcinomas (median follow-up time 91 months, range 24-186 months) and the results were correlated with clinicopathological data and prognostic variables. Sixty-three (25%) tumours were scored bcl-2 negative and 188 (75%) tumours were bcl-2 positive. No relationship could be observed between bcl-2 status and tumour grade, pTNM staging or menopausal status. A strong positive relationship was demonstrated between bcl-2 immunoreactivity and oestrogen receptor status (P < 0.001) and progesterone receptor status (P < 0.001). No prognostic value was demonstrated for bcl-2 expression on disease-free survival and overall survival in axillary node-negative breast cancer patients. However, in axillary node-positive breast cancer patients multivariate analysis demonstrated absence of bcl-2 expression to be independently related to shortened disease-free survival (P = 0.003) and shortened overall survival (P < 0.001). Our results suggest a potential important role for bcl-2 expression as a modulator of response to adjuvant therapy in breast cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|